<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532777</url>
  </required_header>
  <id_info>
    <org_study_id>AZhang</org_study_id>
    <nct_id>NCT02532777</nct_id>
  </id_info>
  <brief_title>The Research of Standard Diagnosis and Treatment for HSPN in Children</brief_title>
  <official_title>The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is performed to evaluate the efficacy and safety of various measures in the
      treatment of HSPN in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Henoch-Schonlein purpura nephritis (HSPN) is one of the most common complications of
      Henoch-Schonlein purpura, and has become one of the main causes of chronic kidney disease in
      children. However, the diagnosis and treatment of HSPN is still based on the clinical
      experience, lacking of evidence-based support. This study is performed to explore the
      biological marker for early prediction of the prognosis and evaluate the efficacy and safety
      of various measures in the treatment of HSPN in children.

      The patients who are proved to get HSPN by renal biopsy will be given prednisone 2mg/kg/d,
      and randomized to receive cyclophosphamide pulse i.v.,mycophenolate mofetil p.o. or
      leflunomide p.o., we will follow up them for about 2.5 years and compare the efficacy and
      safety of these measures by monitoring several indexes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disappearance of proteinuria</measure>
    <time_frame>30 mo</time_frame>
    <description>The proteinuria is &lt; 150mg/d</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disappearance of hematuria</measure>
    <time_frame>30 mo</time_frame>
    <description>The number of red blood cells is &lt; 3 in each high power field of vision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>30 mo</time_frame>
    <description>The glomerular filtration rate is normal</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Henoch-Schoenlein Purpura Nephritis</condition>
  <arm_group>
    <arm_group_label>Prednisone &amp; Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: prednisone &amp; cyclophosphamide &amp; Angiotensin-converting enzyme inhibitor(ACEI).
Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.
cyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone &amp; Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: prednisone &amp; mycophenolate mofetil &amp; Angiotensin-converting enzyme inhibitor(ACEI).
Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.
mycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone &amp; Leflunomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: prednisone &amp; leflunomide &amp; Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.
Leflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d.
Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Prednisone &amp; Cyclophosphamide</arm_group_label>
    <arm_group_label>Prednisone &amp; Mycophenolate mofetil</arm_group_label>
    <arm_group_label>Prednisone &amp; Leflunomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide(CTX)</intervention_name>
    <arm_group_label>Prednisone &amp; Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil(MMF)</intervention_name>
    <arm_group_label>Prednisone &amp; Mycophenolate mofetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide(LEF)</intervention_name>
    <arm_group_label>Prednisone &amp; Leflunomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin-converting enzyme inhibitor(ACEI)</intervention_name>
    <arm_group_label>Prednisone &amp; Cyclophosphamide</arm_group_label>
    <arm_group_label>Prednisone &amp; Mycophenolate mofetil</arm_group_label>
    <arm_group_label>Prednisone &amp; Leflunomide</arm_group_label>
    <other_name>Lotensin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <arm_group_label>Prednisone &amp; Cyclophosphamide</arm_group_label>
    <arm_group_label>Prednisone &amp; Mycophenolate mofetil</arm_group_label>
    <arm_group_label>Prednisone &amp; Leflunomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal biopsy proved HSPN Proteinuria ≥ 50 mg/kg/d

        Exclusion Criteria:

          -  The children with congenital diseases Proteinuria &lt; 50 mg/kg/d
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aihua Zhang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nephrology, Nanjing children's hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aihua Aihua, M.D.</last_name>
    <phone>+8618951769017</phone>
    <email>bszah@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yimei Wu</last_name>
    <phone>+8615951757930</phone>
    <email>wym891203@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing Children's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aihua Zhang, M.D.</last_name>
      <phone>+8618951769017</phone>
      <email>bszah@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Children's Hospital</investigator_affiliation>
    <investigator_full_name>Aihua Zhang</investigator_full_name>
    <investigator_title>Hospital vice president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Purpura, Schoenlein-Henoch</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

